Advanced search
Publication Cover
Autoimmunity Volume 55, 2022 - Issue 2
Submit an article Journal homepage
2,047
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity

Rachel W. Linnemanna Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USACorrespondence[email protected]
View further author information
,
Ruchi Yadavb Department of Infectious Diseases, College of Veterinary Medicine, The University of Georgia, Athens, GA, USAView further author information
,
Chao Zhangc Biostatistics Core, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USAView further author information
,
Demba Sarrb Department of Infectious Diseases, College of Veterinary Medicine, The University of Georgia, Athens, GA, USAView further author information
,
Balázs Radab Department of Infectious Diseases, College of Veterinary Medicine, The University of Georgia, Athens, GA, USAView further author information
&
Arlene A. Stecenkoa Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USAView further author information
Pages 109-117 | Received 16 May 2021, Accepted 17 Dec 2021, Published online: 04 Jan 2022

References

  • Ratjen F, Bell SC, Rowe SM, et al. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010.
  • Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2019 annual data report. Bethesda (MD): Cystic Fibrosis Foundation; 2019.
  • Harun SN, Wainwright C, Klein K, et al. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev. 2016;20:55–66.
  • Sly PD, Brennan S, Gangell C, Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF), et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009;180(2):146–152.
  • Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963–1970.
  • Cantin AM, Hartl D, Konstan MW, et al. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419–430.
  • Witko-Sarsat V, Sermet-Gaudelus I, Lenoir G, et al. Inflammation and CFTR: might neutrophils be the key in cystic fibrosis? Mediators Inflamm. 1999;8(1):7–11.
  • Khan MA, Ali ZS, Sweezey N, et al. Progression of cystic fibrosis lung disease from childhood to adulthood: neutrophils, neutrophil extracellular trap (NET) formation, and NET degradation. Genes (Basel.). 2019;10(3):183.
  • Skopelja S, Hamilton BJ, Jones JD, et al. The role for neutrophil extracellular traps in cystic fibrosis autoimmunity. JCI Insight. 2016;1(17):e88912.
  • Wang Y, Li M, Stadler S, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol. 2009;184(2):205–213.
  • Rohrbach AS, Slade DJ, Thompson PR, et al. Activation of PAD4 in NET formation. Front Immunol. 2012;3:360.
  • Lewis HD, Liddle J, Coote JE, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015;11(3):189–191.
  • Spengler J, Lugonja B, Ytterberg AJ, et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid. Arthritis Rheumatol. 2015;67(12):3135–3145.
  • Yadav R, Yoo DG, Kahlenberg JM, et al. Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis. J Cyst Fibros. 2019;18(5):636–645.
  • Quanjer PH, Stanojevic S, Cole TJ, ERS Global Lung Function Initiative, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343.
  • Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29–34.
  • Yadav R, Linnemann RW, Kahlenberg JM, et al. IgA autoantibodies directed against self DNA are elevated in cystic fibrosis and associated with more severe lung dysfunction. Autoimmunity. 2020;53(8):476–484.
  • Curran AM, Naik P, Giles JT, et al. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol. 2020;16(6):301–315.
  • Reyes-Castillo Z, Muñoz-Valle JF, Llamas-Covarrubias MA. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis. Autoimmun Rev. 2018; 17(2):94–102.
  • Halvorsen EH, Pollmann S, Gilboe IM, et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis. 2008; 67(3):414–417.
  • Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 2008; 58(7):1958–1967.
  • Kolfenbach JR, Deane KD, Derber LA, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633–2639.
  • Willis VC, Banda NK, Cordova KN, et al. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol. 2017 ;188(2):263–274.
  • Gray RD, Hardisty G, Regan KH, et al. Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax. 2018;73(2):134–144.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.